Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy
Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales
Based on evidence for the contribution of hyperglucagonemia to hyperglycaemia in T2D, research demonstrated the use of glucagon antagonism to improve glycaemic control
Un avis mdical reste conseill en cas de traitement mdicamenteux concomitant
(PubMed) Huang K, Duan HQ, Li QX, Luo YB, Yang H
US$ 21.35
US$ 22.69
US$ 26.06
US$ 25.38
US$ 21.69
US$ 26.08
